"Clofazimine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
| Descriptor ID |
D002991
|
| MeSH Number(s) |
D03.633.300.704.353
|
| Concept/Terms |
Clofazimine- Clofazimine
- N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine
|
Below are MeSH descriptors whose meaning is more general than "Clofazimine".
Below are MeSH descriptors whose meaning is more specific than "Clofazimine".
This graph shows the total number of publications written about "Clofazimine" by people in this website by year, and whether "Clofazimine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 5 | 7 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Clofazimine" by people in Profiles.
-
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study. PLoS Negl Trop Dis. 2021 07; 15(7):e0009635.
-
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021 05; 593(7859):418-423.
-
Clofazimine: A potential therapeutic option for severe COVID-19. Med Hypotheses. 2021 05; 150:110535.
-
4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. Int J Mol Sci. 2020 Aug 19; 21(17).
-
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications. Expert Opin Biol Ther. 2019 02; 19(2):79-88.
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
-
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrob Agents Chemother. 2018 12; 62(12).
-
Clofazimine does not lead to significant QT interval prolongation: a multicentre study. Eur Respir J. 2018 11; 52(5).
-
Case Report: Molecular Confirmation of Lobomycosis in an Italian Traveler Acquired in the Amazon Region of Venezuela. Am J Trop Med Hyg. 2017 Dec; 97(6):1757-1760.
-
Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005725.